Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer

Cancer Treatment Reviews

Volumn 35, Issue 8, 2009, Pages 668-675

  Hebbar, Mohamed ^a   Pruvot, François René ^a   Romano, Olivier ^a   Triboulet, Jean Pierre ^a   de Gramont, Aimery ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin; Resectable metastases

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

BILIARY SCLEROSIS; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CATHETER INFECTION; CATHETER THROMBOSIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER DISEASE; LIVER METASTASIS; LIVER RESECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SCLEROSIS; SENSORY NEUROPATHY; SINUSOIDAL DILATION; SURVIVAL RATE; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; FLUOROURACIL; HEPATECTOMY; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LIVER; LIVER NEOPLASMS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70449701509     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.08.005     Document Type: Review

References (108)

1. Wei A.C., Greig P.D., Grant D., Taylor B., Langer B., and Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13 (2006) 668S-676S
2. Curley S.A. Outcomes after surgical treatment of colorectal cancer liver metastases. Semin Oncol 32 (2005) S109-S111
3. Ackerman N.B. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75 (1974) 589-596
4. Miyanari N., Mori T., Takahashi K., and Yasuno M. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 45 (2002) 1503-1509
5. O'Connell M.J., Nagorney D.M., Bernath A.M., et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 16 (1998) 2528-2533
6. Van Riel J.M., van Groeningen C.J., Albers S.H., et al. Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. Ann Oncol 11 (2000) 1563-1570
7. Leonard G.D., Brenner B., and Kemeny N.E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23 (2005) 2038-2048
8. Link K.H., Pillasch J., Formentini A., et al. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 25 (1999) 381-388
9. Meric F., Patt Y.Z., Curley S.A., et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 7 (2000) 490-495
10. Kemeny N., Daly J., Reichman B., Geller N., Botet J., and Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107 (1987) 459-465
11. Chang A.E., Schneider P.D., Sugarbaker P.H., Simpson C., Culnane M., and Steinberg S.M. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206 (1987) 685-693
12. Hohn D.C., Stagg R.J., Friedman M.A., et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7 (1989) 1646-1654
13. Wagman L.D., Kemeny M.M., Leong L., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8 (1990) 1885-1893
14. Martin Jr. J.K., O'Connell M.J., Wieand H.S., et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125 (1990) 1022-1027
15. Meta-Alanysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 88 (1996) 252-258
16. Harmantas A., Rotstein L.E., and Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 78 (1996) 1639-1645
17. Lorenz M., and Müller H.H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18 (2000) 243-254
18. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361 (2003) 368-373
19. Rougier P., Laplanche A., Huguier M., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10 (1992) 1112-1118
20. Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., and Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344 (1994) 1255-1260
21. Kemeny N.E., Niedzwiecki D., Hollis D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24 (2006) 1395-1403
22. Mocellin S., Pasquali S., and Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 4 (2009) CD007823
23. Buyse M., Thirion P., Carlson R.W., Burzykowski T., Molenberghs G., and Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356 (2000) 373-378
24. Elias D., de Baere T., Sideris L., and Ducreux M. Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surg Clin North Am 84 (2004) 607-625
25. Moosman N., Kern W., Waggershauser T., et al. Hepatic infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final results of a phase I/II study. Proc Am Soc Clin Oncol. J Clin Oncol 23 (2005) 3628 [abstr]
26. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23 (2005) 4881-4887
27. Boige V., Malka D., Elias D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15 (2008) 219-226
28. Nonami T, Takeuchi Y, Yasui M, et al. Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma. Semin Oncol 1997; 24: S6-130-S6-134.
29. Ambiru S., Miyazaki M., Ito H., et al. Adjuvant regional chemotherapy after hepatic resection for colorectal metastases. Brit J Surg 86 (1999) 1025-1031
30. Heslin M.J., Medina-Franco H., Parker M., et al. Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival. Arch Surg 136 (2001) 318-323
31. Kokudo N., Seki M., Ohta H., et al. Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases. Ann Surg Oncol 5 (1998) 706-712
32. Curley S.A., Roh M.S., Chase J.L., and Hohn D.C. Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg 166 (1993) 743-746
33. Gambiez L., Denimal F., Karoui M., et al. Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients. Chirurgie 124 (1999) 640-648
34. Tono T., Kanoh T., Ohnishi T., et al. Adjuvant hepatic arterial infusion after curative resection of colorectal liver metastases using removable intra-arterial catheters with shape-memory alloy. J Surg Oncol 88 (2004) 248-255
35. Tono T., Hasuike Y., Ohzato H., et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomized study. Cancer 88 (2000) 1549-1556
36. Kemeny N., Conti J.A., Sigurdson E., et al. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer 71 (1993) 1964-1971
37. Scaife C.L., Curley S.A., Izzo F., et al. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol 10 (2003) 348-354
38. Lorenz M., Muller H.H., Schramm H., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228 (1998) 756-762
39. Nelson R., and Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev 4 (2006) CD003770
40. Kusunoki M., Yanagi H., Noda M., et al. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 89 (2000) 1228-1235
41. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23 (2005) 4888-4896
42. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23 (2005) 4881-4887
43. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341 (1999) 2039-2048
44. Kemeny N.E., and Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 352 (2005) 734-735
45. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318
46. Kemeny M.M., Adak S., Gray B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 20 (2002) 1499-1505
47. Kemeny N., Capanu M., D'Angelica M., et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 20 (2009) 1236-1241
48. Martin R.C., Edwards M.J., and McMasters K.M. Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver. Am J Surg 188 (2004) 714-721
49. Figueras J., Valls C., Rafecas A., Fabregat J., Ramos E., and Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Brit J Surg 88 (2001) 980-985
50. Portier G., Elias D., Bouche O., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24 (2006) 4976-4982
51. Langer B., Bleiberg H., Labianca R., et al. Fluorouracil plus l-leucovorin versus observation after potentially curative resection of liver or lung metastases from colorectal cancer. Proc Am Soc Clin Oncol. J Clin Oncol 20 (2002) 592 [abstr]
52. Mitry E., Fields A.L., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26 (2008) 4906-4911
53. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
54. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
55. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
56. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8 (2001) 347-353
57. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
58. Wein A., Riedel C., Bruckl W., et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-h infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64 (2003) 131-138
59. Mackay H.J., Billingsley K., Gallinger S., et al. A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases. Am J Clin Oncol 28 (2005) 547-554
60. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
61. Ychou M., Hohenberger W., Thezenas S., et al. Fluorouracil/folinic acid (LV5FU) versus LV5FU + irinotecan (LV5FU + IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer. (CPT-GMA-301). Proc Am Soc Clin Oncol. J Clin Oncol 28 (2008) LBA4013 [abstr]
62. Saltz L.B., Niedzwiecki D., Hollis D., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25 (2007) 3456-3461
63. Ychou M., Raoul J.L., Douillard J.Y., et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20 (2009) 674-680
64. Van Cutsem E., Labianca R., Bodoky G., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27 (2009) 3117-3125
65. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004) 1052-1061
66. Hebbar M., Tournigand C., Lledo G., et al. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest 24 (2006) 154-159
67. Taïeb J., Artru P., Paye F., et al. Intensive chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. Phase II trial assessing the new regimens (6 FOLFOX followed by 6 FOLFIRI) in patients with resectable metastases. Promising schedule currently assessed in a phase III trial. J Clin Oncol 23 (2005) 502-509
68. Bolton J.S., and Fuhrman G.M. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 231 (2000) 743-751
69. Nordlinger B., Van Cutsem E., Gruenberger T., et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20 (2009) 985-992
70. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (2007) 1670-1676
71. Masi G., Loupakis F., Pollina L., et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249 (2009) 420-425
72. Rivoire M., Thezenas S., Rebischung C., et al. Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (METHEP). Proc Am Soc Clin Oncol. J Clin Oncol 26 Suppl. (2008) 4075 [abs]
73. Kooby D.A., Fong Y., Suriawinata A., et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7 (2003) 1034-1044
74. Fong Y., and Bentrem D.J. CASH (Chemotherapy-Associated Steatohepatitis) costs. Ann Surg 243 (2006) 8-9
75. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
76. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
77. Pawlik T.M., Olino K., Gleisner A.L., Torbenson M., Schulick R., and Choti M.A. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11 (2007) 860-868
78. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 6 (2005) 845-853
79. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24 (2006) 4983-4990
80. Karoui M., Penna C., Amin-Hashem M., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006) 1-7
81. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
82. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 24 (2006) 3939-3945
83. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
84. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007) 1539-1544
85. Cassidy J., Cunningham D., Berry S.R., et al. Surgery with curative intent in patients treated with first-line chemotherapy + bevacizumab for metastatic colorectal cancer: First BEAT and NO16966. Proc Am Soc Clin Oncol. J Clin Oncol 26 Suppl. (2008) 4022 [abs]
86. Falcone A., Masi G., Loupakis F., et al. FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab in the first-line treatment of metastatic colorectal cancer: a phase II study by the G.O.N.O. group. Proc Am Soc Clin Oncol. J Clin Oncol 26 Suppl. (2008) 4031 [abs]
87. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24 (2006) 3354-3360
88. Korsisaari N., Kasman I.M., Forrest W.F., et al. Inhibition of VEGF-A prevents the angiogenic s6witch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci USA 104 (2007) 10625-10630
89. Takeda A., Stoeltzing O., Ahmad S.A., et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9 (2002) 610-616
90. Ellis L.M., Curley S.A., and Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23 (2005) 4853-4855
91. Michael M., Van Cutsem E., Kretzschmar A., et al. Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - preliminary results from the First Beat-study. Proc Am Soc Clin Oncol. J Clin Oncol 24 (2006) 3523 [abstr]
92. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26 (2008) 1830-1835
93. Kesmodel S.B., Ellis L.M., Lin E., et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26 (2008) 5254-5260
94. Abdalla E.K., Eng C., Madary A., Vauthey J.N., and Southwest Oncology Group 0408. Southwest Oncology Group 0408: phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver. Clin Colorectal Cancer 5 (2006) 436-439
95. Hecht J.R., Trarbach T., Jaeger E., et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol. J Clin Oncol 23 (2005) 3 [abstr]
96. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
97. Tabernero J., Van Cutsem E., Díaz-Rubio E., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25 (2007) 5225-5232
98. Raoul J.L., Van Laethem J.L., Peeters M., et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 9 (2009) 112
99. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc Am Soc Clin Oncol. J Clin Oncol 25 Suppl. (2007) 4000 [abstr]
100. Van Cutsem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol. J Clin Oncol 26 Suppl. (2008) 2 [abstr]
101. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. Proc Am Soc Clin Oncol. J Clin Oncol 26 (2008) 4000 [abstr]
102. Hecht J.R., Mitchell E., Chidiac T., et al. An updated analysis of safety and efficacy of oxaliplatin/bevacizumab panitumumab for first-line treatment of metastatic colorectal cancer from a randomized, controlled trial (PACCE). Proc Am Soc Clin Oncol - Gastrointest Cancers (2008) 273 [abs]
103. Kuo T., Cho C.D., Halsey J., et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 5613-5619 20
104. Messersmith W.A., Laheru D.A., Senzer N.N., et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10 (2004) 6522-6527
105. Santoro A., Comandone A., Rimassa L., et al. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol 19 (2008) 1888-1893
106. Veronese M.L., Sun W., Giantonio B., et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Brit J Cancer 92 (2005) 1846-1849
107. Cascinu S., Berardi R., Salvagni S., et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Brit J Cancer 98 (2008) 71-76
108. Fisher G.A., Kuo T., Ramsey M., et al. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res 14 (2008) 7074-7079